CLINICAL TRIALS PROFILE FOR TAFAMIDIS MEGLUMINE
✉ Email this page to a colleague
All Clinical Trials for TAFAMIDIS MEGLUMINE
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT01435655 ↗ | The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin | Completed | Pfizer | Phase 3 | 2011-11-01 | Tafamidis has been developed as an oral specific stabilizer of transthyretin tetramer. |
NCT01994889 ↗ | Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy | Completed | Pfizer | Phase 3 | 2013-12-09 | This Phase 3 study will investigate the efficacy, safety and tolerability of an oral daily dose of 20 mg or 80 mg tafamidis meglumine capsules compared to placebo in subjects with either transthyretin genetic variants or wild-type transthyretin resulting in amyloid cardiomyopathy. |
NCT02791230 ↗ | Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy | Active, not recruiting | Pfizer | Phase 3 | 2016-06-13 | Open label study to evaluate tafamidis for the treatment of transthyretin cardiomyopathy |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TAFAMIDIS MEGLUMINE
Condition Name
Clinical Trial Locations for TAFAMIDIS MEGLUMINE
Trials by Country
Clinical Trial Progress for TAFAMIDIS MEGLUMINE
Clinical Trial Phase
Clinical Trial Sponsors for TAFAMIDIS MEGLUMINE
Sponsor Name